The art of targeting cancer therapies: an interview with Professor Paul Workman
15 September 2008
Malini Guha
Please Login to read the full article.
15 September 2008
Malini Guha
malini.guha@informa.com
Whilst there have been many successes in Professor Paul Workman's 30-year career in cancer drug development, the past year arguably serves as the greatest testament to the quality of his endeavours. In April,
Roche, the large pharma company most focused on cancer drug development, announced that...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Aveo licences preclinical RON-targeted antibodies to J&J, for $15 million up front
- Gilead's $375 million Calistoga buy signals shift into oncology and inflammation
- Yakult expands oncology pipeline with Proacta deal
- White House extols achievements of teen drug innovators, scientists
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
